Navigation Links
Response Genetics Reports Second Quarter 2007 Financial Results
Date:8/19/2007

rily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of Response Genetics, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze pancreatic cancer samples, the potential for using the results of this research to develop diagnostic tests for pancreatic cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward- looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's
'/>"/>

SOURCE Response Genetics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... (PRWEB) April 24, 2015 Seoul ... technology for various applications in the lighting market. ... successful installations of this technology in emerging markets ... for a wide range of applications such as ... and decorative lighting. , First launched in 2005 ...
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)... April 23, 2015 Six startups ... on April 4-17 as part of the U.S.-Russia ... fourth group of biotechnology startups to participate in ... Novgorod (UNN) and the University of Maryland (UMD) ... between their respective universities in the biomedical industry ...
(Date:4/23/2015)... (PRWEB) April 23, 2015 ... refer to a series of genetic tests that ... fibrosis, Lou Gehrig's disease, Huntington's disease, and Alzheimer's ... the gene composition and interaction in diseased tissue/cells ... as well as the response to treatment, such ...
Breaking Biology Technology:Acrich Technology from Seoul Semiconductor Adopted in Installations Worldwide 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3
... Pharmaceuticals, a,division of Wyeth (NYSE: WYE ... for XYNTHA(TM) Antihemophilic Factor (Recombinant),Plasma/Albumin-Free, a new ... and prevention of bleeding episodes and surgical ... inherited blood-clotting disorder., XYNTHA is produced ...
... Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it ... trial using intravenous,administration of REOLYSIN(R) in combination with ... neck cancers. The Principal,Investigator is Dr. Monica Mita ... The University of Texas Health Science Center at ...
... Senior-friendly ,PlanPrescriber, Software Simplifies Medicare - For Free, ... today,announced the latest release of their PlanPrescriber tool. ... worry about whether they are,getting the most out ... MIT Professor Glen Urban, provides users with easy ...
Cached Biology Technology:New Recombinant XYNTHA Now Available for Patients with Hemophilia A 2New Recombinant XYNTHA Now Available for Patients with Hemophilia A 3New Recombinant XYNTHA Now Available for Patients with Hemophilia A 4New Recombinant XYNTHA Now Available for Patients with Hemophilia A 5Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3On-Line Medicare Advisor Saves Seniors Time, Hassle and Money 2
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... April 13, 2015  higi, a leading cloud-based consumer ... more fully engage with their communities around health and ... protected and secure API.  ... most accessible, affordable, and convenient vehicle to receive validated ... The API will allow higi,s trusted ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... MADISON, WI, NOVEMBER 9, 2009 -- ... as a result of their presence in wastes (sewage ... long periods of time. Regulations and guidelines for tolerable ... based on the assumption that the toxic effects of ...
... for use by the U.S. Food and Drug Administration ... growth and invasiveness of ovarian cancer cells and also ... Jonsson Comprehensive Cancer Center found. The drug, when ... in fighting ovarian cancer in cell lines in which ...
... California and elsewhere provide support for the use of ... protecting marine habitats, according to biologists at the University ... in the Gulf of California, for example, confirmed the ... that offspring produced in a protected area can replenish ...
Cached Biology News:Additive copper-zinc interaction affects toxic response in soybean 2FDA approved leukemia drugs shows promise in ovarian cancer cells 2Studies show marine reserves can be an effective tool for managing fisheries 2Studies show marine reserves can be an effective tool for managing fisheries 3Studies show marine reserves can be an effective tool for managing fisheries 4Studies show marine reserves can be an effective tool for managing fisheries 5
... Quidel's depleted sera are specifically depleted ... exception of the depleted protein, the alternative ... reagents are therefore ideal for the detection ... ,Depleted sera have been used to assess ...
... by luciferase-cDNA transfected cell lines has proven ... development of reporter gene assays in which ... for the transcription of other genes. The ... to advantages such as high sensitivity and ...
... is a technique used to reveal two ... Staining Kit is a Zymed polymer double ... simultaneously in the same human cell or ... can be identified using two different primary ...
... the D-2000, but comes with a shutter (controlled ... The D-2000 Deuterium Light Source produces a ... deep-UV versions of the light source are available, ... powerful and stable lamp provides peak-to-peak stability of ...
Biology Products: